AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06104410 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard fractioned dose
Description: Total dose of 6 Gy in 2 or 4 single fractions of 1.5 Gy applied twice weekly.
Study NCT06104410 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental single dose
Description: Total dose of 0.5 Gy, 1Gy, 1.5 or 2Gy in 1 single fraction.
Study NCT05538156 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group
Description: Vitrectomy and gas tamponade without internal limiting membrane peeling
Study NCT05538156 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intervention group
Description: Vitrectomy, internal limiting membrane peeling and gas tamponade
Study NCT05855499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPtcube, CPTpatch
Description: This study investigates the effectiveness of a system for reproducible application of cold plasma on larger areas and observes the effect of a 4-week additional plasma treatment on wound healing of large chronic wounds.
Study NCT05418335 — intervention group
Intervention type: OTHER
Intervention: Clinical examination, functional status evaluation
Description: Barthel Index, Oral Health Impact Profile 14, Beck Depression Inventory, Stroke Impact Scale 3, Plaque Index, Calculus Index, Periodontal Disease Index, Simplified Oral Hygiene Index assesment, DMFT Index
Study NCT05225285 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Coronavac/Butantan vaccine
Description: Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
Study NCT05225285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Coronavac/Butantan vaccine
Description: Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
Study NCT05225285 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 (Pfizer)
Description: BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart
Study NCT05530928 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reproductive life plan counseling
Description: The intervention group will receive in addition to the standard contraceptive counseling, a reproductive life plan counseling: midwives will discuss the different options with the woman depending if she wants or not more children, and she will give her general information about preconception health.
Study NCT06577142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burn 2 Learn
Description: The 'Burn 2 Learn' group encompassed the following components and implementations. A brief introductory seminar will be conducted with the principle, school event coordinator, school sports teacher and students from grade 8 to 10. The aim of this seminar is to provide a better understanding of the rationale and presenting evidence of the beneficial effects of high intensity interval training on overall wellbeing of students. The sessions will be conducted thrice a week for 10 to 15 minutes by the research team members for a period of 10 weeks. The sessions will consist of high intensity interval training activities such as lunges, jumping jacks, boxing, dancing and sports activities. The intervals ranging between 8-16, 30 second work out followed by 30 seconds rest, maintaining a 1:1 work rest ratio.~51 participants will be in the experimental group A giving them Burn 2 Learn exercise protocol along with the normal sports training plan for ten weeks.
Study NCT06577142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: 51 participants will be in control group B and will perform their routine school physical activities, sports games or any exercise routines.
Study NCT06443957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal normal saline
Description: The patient was given 1ml of normal saline intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
Study NCT06443957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin-20U
Description: The patient was given 1ml of 20U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
Study NCT06443957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin-40U
Description: The patient was given 1ml of 40U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
Study NCT05487937 — intervention group
Intervention type: OTHER
Intervention: Use of Toleriane Ultra to relieve face allergic skin
Description: The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
Study NCT06134284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib combined with rituximab
Description: This is a single-arm trial. Patients with relapsed/refractory marginal zone lymphoma will be treated with the OR regimen. The treatment plan is as follows: Orelabrutinib 150mg oral administration once a day, Day 1-21; Rituximab 375mg/m² intravenous infusion, Day 1. Each cycle is 21 days. PET-CT evaluation will be conducted after 4 cycles. If a partial response (PR) or better is achieved, the patient will receive further treatment with the OR regimen for an additional 4 cycles before transitioning to single-agent maintenance therapy with either rituximab or obinutuzumab. If a PR or better is not achieved after 4 cycles, the patient will discontinue from the trial.
Study NCT05871047 — intervention group
Intervention type: DEVICE
Intervention: tragus to wall distance (TWD), craniovertebral angle (CVA) by smart phone application
Description: Applying photogrammetric method for CVA by smart phone application and measure nerd neck objectively from both sitting and standing positions. Also, tragus to wall distance method was used to detect degree of nerd neck from the standing position.
Study NCT05190770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Triamcinolone acetonide is a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. It is applied topically.
Study NCT05190770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone acetonide is a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. It is applied topically.
Study NCT05190770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10
Description: Oleogel-S10 consists of birch bark extract (TE): 10 mg/100 mg; Sunflower oil, refined: 90 mg/100 mg. It is applied topically.
Study NCT06271785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HR-EEG recording
Description: All participants will have a HR-EEG recordings. It will be made at rest. Nap-like sleep is encouraged, but no sedatives will be given. Recording time will not exceed two hours.
Study NCT04548193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive live phone call
Study NCT04548193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Dietary Intervention
Description: Receive live phone call
Study NCT04548193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive IVR phone messages
Study NCT04548193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Dietary Intervention
Description: Receive IVR phone messages
Study NCT04548193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT04548193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT04548193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04548193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05921929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoroethylnormemantine (FENM)
Description: Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
Study NCT05558241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution micro-ultrasound
Description: In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
Study NCT06139471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Enhanced Gagne's Instructional Model
Description: Virtual Reality-Enhanced Gagne's Instructional Model
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT05716971 — intervention group
Intervention type: PROCEDURE
Intervention: Densiron-68 (heavy silicone oil) tamponade for retinal detachment
Description: pars plana vitrectomy using Densiron-68 at thee end of surgery
Study NCT06113822 — intervention group
Intervention type: DEVICE
Intervention: ultrasonography
Description: We used ultrasonography to measure the patients' masseter muscle thickness. Measurements were performed simultaneously for both the right and left sides using a high frequency linear scanning probe (13-6 MHz) of an ultrasound device (Fujifilm Sonosite Edge II). In order to prevent possible artifacts and oblique imaging, the probe was kept perpendicular to the skin surface, and the distance between the location of the hyperechoic linear appearance of the mandibular and temporal bone in the transverse section and the muscular fascia were measured.
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Given IV
Study NCT04637594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT06342713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-45035
Description: Administered orally
Study NCT06342713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT05360147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.
Study NCT05360147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides
Description: oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
Study NCT04933747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Administration of a single oral dose of 1mg iberdomide in participants
Study NCT04933747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
Study NCT04871490 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for HPV DNA
Description: All participants will have blood tested for HPV DNA.
Study NCT06578689 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education
Description: The control group received standard care, while the intervention group received standard care supplemented with formal educational session followed by ongoing education on foot care using mobile health by a clinical pharmacist.
Study NCT06576986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: The synbiotic used will be Simbioflora® (commercial preparation containing 5.5g of FOS added with four species of probiotic, Lactobacillus paracasei LPC-31; Lactobacillus rhamnosus HN001; Lactobacillus acidophilus NCFM; Bifidobacterium lactis HN019, at a concentration of 109 UFC per strain) supplied by Farmoquímica S.A. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.
Study NCT06576986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin, used as control, will be purchased from the company PRODIET® under the trade name Carboch®. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.
Study NCT06359821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZA-001
Description: Study drug ZA-001 administered via intravenous injection.
Study NCT04751955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olinvacimab added to Capecitabine
Description: Olinvacimab: IV weekly administration In phase lb, 12mg/kg and 16mg/kg weekly IV will be tested. In phase ll, the RP2D in phase lb will be used. Capecitabine: fixed dose as an oral administration, 1250mg/m2 BID on day 1 to 14 followed by 7 days off
Study NCT06175078 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Imaging 3D and Spectroscopy
Description: Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
Study NCT05540847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interfascial Injection
Description: Interfascial Injection on Ultrasound-guided Obturator Nerve Block
Study NCT05540847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subpectineal Injection
Description: Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
Study NCT05056259 — intervention group
Intervention type: DEVICE
Intervention: 18F-FDG PET/CT
Description: The PET/CT procedure will be performed according to the institutional standard with 18F-FDG (0.8-1.2 mCi /kg) injection following 6 h fasting. Blood glucose was controlled to be \<150 mg/dl. PET/CT from the vertex to the middle femur will be obtained 60 min after FDG injection.~MDCT examination without IV contrast will be done for attenuation correction and anatomic localization followed by PET images from the skull vault to the mid-thigh region.~Images of CT and corresponding functional PET images are displayed in axial, coronal and sagittal planes.~PET/CT data will include tumor size and extension, LN invasion\& distant metastasis SUVmax will be calculated for all positive lesions, Metabolic parameters including SUVmax, SUVmean, TLG \& MTV will be calculated for primary tumor.~Data of PET will be compared with other diagnostic imaging and postoperative pathologic data.
Study NCT05831332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7
Description: Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
Study NCT04267809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 500mg tablets are registered and licensed in Singapore. For the study, we will be sourcing the Metformin tablets from Singapore General Hospital Formulary.
Study NCT04267809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Calcium and Vitamin D tablets are registered and licensed in Singapore. For the study, we will be sourcing the Calcium and Vitamin D tablets from Singapore General Hospital Formulary.
Study NCT05704283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo 3D-US
Study NCT04827953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
Study NCT04827953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
Study NCT04827953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLM-001
Description: NLM-001 will be administered three cycles consecutively followed by two rest cycles.
Study NCT04827953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalifrelimab
Description: Zalifrelimab administration each 6 weeks.
Study NCT04892329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assistant system
Description: The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
Study NCT05693064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wait-list
Description: wait-list
Study NCT05693064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chiropractic adjustments
Description: chiropractic adjustments
Study NCT06272539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise The exercise will be adapted according to the phases based on the results already published, limiting in each phase the degrees of flexion and extension of the spine in order to avoid the risk of electrode migration.
Study NCT06272539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy
Study NCT06272539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy
Study NCT05669417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.
Study NCT05669417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulfate
Description: Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.
Study NCT04494490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Practice Guidelines and Psychologically Informed Physical Therapy training/audit/feedback
Description: The aim of the active training strategy is to improve the knowledge and skills of physical therapists with regard to evidence-based physical therapy with an emphasis on active treatments and PIPT for the treatment of patients with low back pain and to encourage increased adherence with CPGs. This Continuing Education (CE) training session will be offered to all therapists regardless of study participation. During the CE training session, focus will be placed on interventions that have been shown to be effective, such as interactive education and discussion, feedback, and reminders.
Study NCT04968080 — intervention group
Intervention type: DEVICE
Intervention: Infrared Cameras Inc. (ICI) FMX 400 Infrared (IR) Camera System
Description: Infrared thermal camera
Study NCT04968080 — intervention group
Intervention type: DEVICE
Intervention: Welch Allyn SureTemp Plus 690
Description: Oral thermometer
Study NCT04968080 — intervention group
Intervention type: DEVICE
Intervention: Welch Allyn ThermoScan PRO 6000
Description: Ear thermometer
Study NCT04968080 — intervention group
Intervention type: DEVICE
Intervention: Infrared Cameras Inc. (ICI) HotSpot Infrared (IR) NonContact Infrared Thermometer
Description: Forehead temperature gun